SYK Trading Cheat Sheet — Know This Before You Touch It

Not a table. Not a scorecard. Just the stuff that actually matters if you’re sizing into this name or already in it.

The setup at a glance

• Stock is off roughly 24% from 52-week highs — that’s not a blip, that’s a real drawdown worth understanding before entering
• Current price range has been consolidating, not collapsing — the tape isn’t in freefall, it’s digesting
• The pullback came partly on broader med-tech sector rotation and post-acquisition debt concerns, not deteriorating fundamentals
• Revenue growth is still double-digits. That’s the part the price doesn’t fully reflect yet

Entry zones worth watching

• Aggressive entry: current levels if you believe the debt concern is already priced in
• Conservative entry: wait for a confirmed higher low on the weekly — less upside, more confirmation
• Scale-in approach: split the position, first tranche now, second after next earnings print (Q3 2026 results are the real tell on Inari integration)
• Avoid chasing any gap-up open without a pullback to entry — this isn’t a momentum stock, it’s a compounder

Where the risk actually sits

• Total debt: $15.9B — manageable but it’s there, and if rates stay elevated it matters more than people think
• Inari Medical integration: still early, still unproven at scale — two to three quarters before you have real visibility
• Hospital capex is the hidden variable — if health systems freeze spending in a recession, elective procedure volumes slow and Stryker feels it
• Stop consideration: a clean break below the most recent consolidation low changes the thesis structurally — that’s a reassess moment, not a hold-and-hope

Catalysts on the calendar

• Next earnings: watch MedSurg segment growth rate — if it stays above 12% YoY, the bull case is intact
• Mako robotic system install numbers: any acceleration in placements is a direct signal that recurring revenue is compounding
• Inari revenue contribution: first full year post-acquisition — if vascular beats low expectations, stock re-rates fast
• Any macro clarity on hospital spending (Medicare reimbursement updates, policy changes) moves this name in either direction

What you own if you buy this

• A $25B revenue business growing 11%+ with 63.9% gross margins
• The dominant robotic surgery platform in orthopedics (Mako) — surgeons don’t switch, hospitals don’t either
• A demographic tailwind that doesn’t have a policy risk or a competitive disruption attached to it
• A dividend that paid out $1.28B in 2025 — this isn’t a pure growth story, there’s income here too
• Debt that’s real but serviceable at current cash flow levels — not a crisis, just an overhang

Time horizon matters here. If you’re trading this quarter to quarter, the debt noise and integration uncertainty will grind on you. If you’re holding two to five years, the demographic math does most of the work and you’re probably fine paying today’s price.

There’s a version of this story where I try to make it complicated. I’m not going to do that.

Seventy-three million baby boomers are aging through the system right now. The oldest are approaching 80. The youngest are pushing 62. By 2030, every single one of them will be 65 or older – and that cohort will represent one in five Americans. Joints wear out. Cartilage thins. Hips and knees that carried people through decades of work and weekend runs eventually give out. That’s not a market thesis. That’s physiology.

Stryker builds the hardware that fixes them.

Full-year 2025 revenue came in at $25.1 billion, up 11.2% from the prior year. Net earnings hit $3.2 billion – a 55.5% jump versus 2024. The orthopedics segment generated $9.5 billion on its own. MedSurg and Neurotechnology added $15.6 billion at a 15.7% clip. Management guided 2026 at 8% to 9.5% sales growth, and analyst consensus has EPS climbing from $8.49 last year to roughly $12.74 next year. That’s the kind of number that stops you mid-scroll.

The stock is down about 24% from its highs.

Here’s the thing about pullbacks in businesses with structural demand – they’re uncomfortable to buy and usually obvious in hindsight. The bear case on Stryker isn’t that the aging trend reverses. Nobody’s making that argument. The real friction is the balance sheet. Stryker carried $15.9 billion in total debt going into 2026, including $3.0 billion in new senior notes issued last year to fund roughly $5 billion in acquisitions – Inari Medical being the headline deal. Inari moves Stryker into venous thromboembolism treatment, which is adjacent to its core and not a bad space to be in, but the debt is real and the integration is still early.

Worth sitting with that for a second before moving on.

The rest of the business, though, is genuinely hard to argue with. Gross margins sit around 63.9%. R&D spend hit $1.62 billion in 2025. The Mako robotic surgery platform – Stryker’s most durable competitive asset – creates an installed-base effect that most investors underestimate. Surgeons trained on Mako don’t retrain. Hospital systems that build workflows around it don’t switch vendors mid-decade. That stickiness is what separates Stryker from a commodity implant supplier, and it’s not something a competitor replicates in a quarter or two.

Slight tangent – and this actually matters for the long-term picture – the aging story isn’t a U.S.-only event. Europe is older than America by most demographic measures. Japan has been in structural demographic decline for years. Southeast Asia is accelerating through the same curve. Stryker has international exposure, which means the total addressable market for orthopedic hardware isn’t hitting a ceiling anytime soon. If anything, the global denominator keeps expanding.

The part people skip when they look at this name: the MedSurg and Neurotechnology segment is now the majority of total revenue and growing faster than orthopedics. Endoscopy, neurovascular products, hospital equipment – none of that is tied exclusively to joint replacements. It means Stryker isn’t a single-procedure bet. The demographic tailwind is real, but the business is more diversified than the elevator pitch suggests.

Key numbers, for reference:

• FY2025 revenue: $25.1B (+11.2% YoY)
• Orthopedics: $9.5B (organic growth 9.3%)
• MedSurg & Neurotechnology: $15.6B (+15.7% YoY)
• Gross margin: ~63.9%
• Net earnings: $3.2B (+55.5% YoY)
• R&D: $1.62B
• Cash: $4.1B | Total debt: $15.9B
• 2026 guidance: +8% to +9.5% sales growth
• 3-year forward CAGR (consensus): ~7.7–7.9%
• Dividend paid in 2025: $1.28B

What matters is where the risk actually lives. It’s not demand. Demand is not the variable. The risk is hospital capex freezing in a downturn, debt servicing pressure if rates stay elevated longer than expected, and whether Inari integrates cleanly or creates noise in the next two to three earnings cycles. Those are real. They’re also manageable at Stryker’s scale and cash flow profile – but they explain why the stock is where it is.

Here’s where I’m at on this. A 24% pullback in a business with $25 billion in revenue, 63%+ gross margins, a defensible robotics moat, and a demographic tailwind that compounds for another decade is not a situation I find easy to ignore. The debt is the asterisk. The valuation isn’t stretched the way it was at the highs. And the demand curve – 73 million people aging through a healthcare system that needs orthopedic hardware – that part is already written. Nobody’s lobbying against it. It doesn’t have an off switch. Stryker either captures it or someone else does, and right now, Stryker is the one with the installed base, the distribution, and the robotic platform that keeps surgeons in its ecosystem.

The question I keep coming back to isn’t whether the thesis is intact. It is. The question is whether the market needs one more quarter of clarity before it agrees with you.